Search

everythinglearnresearchcommunity

for

Search:↓

The document emphasizes standardized, comprehensive training for dermatology and venereology specialists across Europe.

Tangent screens help detect visual field defects from vigabatrin.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

Extracellular vesicles show promise for treating diseases but face challenges in development and regulation.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

Certain medications can cause serious side effects, so it's important to report them.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.

Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

UK courts and the European Patent Office are now more open to granting patents for new dosage regimes.

A new method uses expert reviews of home videos to objectively assess children's developmental milestones in single-arm trials.

Recent legal rulings favored Genentech, Teva, and upheld guidelines for patent term extensions.

The study found that combining different databases gives a better estimate of drug side effects in hospitals.

Timely treatment of eosinophilic asthma in rheumatic disease patients can prevent organ damage.

Dermoscopy helps diagnose skin issues and warns against unqualified treatments.

Skin reactions to drugs are common and can be deadly, usually requiring stopping the drug and may be better prevented with genetic testing in the future.

The document concludes that corticosteroids effectively treat vasculitis allergica in over 90% of cases, with long-term kidney issues being the main adverse outcome.

Young patients with Vogt-Koyanagi-Harada syndrome may have poor vision outcomes despite treatment due to frequent recurrences.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.

Vogt-Koyanagi syndrome often leads to partial or complete blindness and responds poorly to treatment.

A sick foal with Rhodococcus equi pneumonia was successfully treated for multiple complications with targeted therapy and careful monitoring.

In 2023, there were major advancements in skin and venereal disease treatments.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.

KRDQN effectively predicts adverse drug reactions with high accuracy and clear explanations.

The new cream is safe and effective for mild to moderate atopic dermatitis.